References
- Ekström P, Carling L, Wetterhus S, Wingren P E, Anker-Hansen O, Lundegårdh G, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996; 31: 753–8
- Morgan G P. Deleterious effects of prostaglandin E2 in reflux oesophagitis. Med Hypotheses 1996; 46: 42–4
- Sarosiek J, McCallum R W. Esophagoprotection by prostaglandins: how far are we from reaching the verdict?. Am J Gastroenterol 1995; 90: 847–9
- Morgan G P. NSAIDs pill oesophagitis. Int J Gastroenterol 1996; 1: 14–6
- Morgan G P. Esophagoprotection with NSAIDs: the way forward. Am J Gastroenterol 1996; 91: 1277
- Morgan G P. NSAIDs and the chemoprevention of colorectal and oesophageal cancer. Gut 1996; 38: 646–8
- Morgan G P. Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis. Med Hypotheses
- Schieman J M, Patel P M, Henson E K, Nostrant I P N, Nostrant T T. Effect of naproxen on gastroesophageal reflux and esophageal function: a randomised, double-blind, placebo-controlled study. Am J Gastroenterol 1995; 90: 754–7